Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 16, 2011, Pages 2433-2439

  Castellano, Daniel ^a   Gonzláez Larriba, José L ^b   Antón Aparicio, Luis M ^c   Cassinello, Javier ^d   Grande, Enrique ^e   Esteban, Emilio ^f   Sepúlveda, Juan ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f Central University Hospital of Asturias   (Spain)

Author keywords

angiogenesis; crpc; daily practice; prostate cancer; psa; sunitinib

Indexed keywords

DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SUNITINIB;

AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE METASTASIS; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDICAL SOCIETY; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; RASH; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANEMIA; ANGIOGENESIS INHIBITORS; CASTRATION; DIARRHEA; DRUG RESISTANCE, NEOPLASM; FATIGUE; HAND-FOOT SYNDROME; HUMANS; INDOLES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRROLES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 80054052140     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.590132     Document Type: Article

References (27)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8 (Pubitemid 40458328)
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12 (Pubitemid 39315317)
3. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20 (Pubitemid 39315318)
4. Sartor AO, Oudard S, Ozguroglu M. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC) [abstract 9]. Presented at the American Society of Clinical Oncology (ASCO) 2010 Genitourinary Cancers Symposium, 5 -7 March 2010, San Francisco, California, USA
5. de Bono J, Logothetis CJ, Fizazi K, et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized, double-blind, placebo-controlled Phase III study [abstract LBA5]. Presented at the 35th ESMO Congress; 11 October 2010, Milan, Italy
6. Berthold DR, Pond GR, de Wit R, et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or viceversa. Ann Oncol 2008;19:1749-53
7. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a Phase II study. Eur Urol 2008;54:1089-94
8. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010;28(20 Suppl): abstract LBA4511
9. Ebos JM, Lee CR, Bogdanovic E, et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008;68:521-9 (Pubitemid 351380080)
10. Kong D, Wang Z, Sarkar SH, et al. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008;26:1425-35
11. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90
12. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006;368:1329-38 (Pubitemid 44528723)
13. Guerin O, Formento P, Lo Nigro C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008;134:51-7 (Pubitemid 350060684)
14. Cumashi A, Tinari N, Rossi C, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008;270:229-33
15. Michaelson MD, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20:913-20
16. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2009;21:319-24
17. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 1999;17:3461-7 (Pubitemid 29517916)
18. World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research involving human subjects. Available from: [Last accessed 15 January 2009]
19. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a Phase II study. Eur Urol 2008;54:1089-94
20. Horti J, Widmark A, Stenzl A, et al. A randomized, double-blind, placebo-controlled Phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm 2009;24:175-80
21. Zurita AJ, Liu G, Hutson T, et al. Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC) [abstract 5166J]. Clin Oncol 2009;27(Suppl):15s
22. Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a Phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009;103:1636-40
23. Nelius T, Klatte T, de Riese W, et al. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol 2009;27:363-7
24. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75
25. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68
26. Collette L. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol 2008;53:6-9 (Pubitemid 350166730)
27. Georgiou HD, Namdarian B, Corcoran NM, et al. Circulating endothelial cells as biomarkers of prostate cancer. Nat Clin Pract Urol 2008;5:445-54